Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-08-17), Gentian Diagnostics AS's 1-Year Sharpe Ratio is -0.67.
Gentian Diagnostics AS (OSL:GENT) 1-Year Sharpe Ratio Explanation
The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.
The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.
Gentian Diagnostics AS 1-Year Sharpe Ratio Related Terms
OSL:GENT vs ABT, SYK, MDT: 1-Year Sharpe Ratio Comparison
For the Medical Devices subindustry, Gentian Diagnostics AS's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gentian Diagnostics AS 1-Year Sharpe Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gentian Diagnostics AS's 1-Year Sharpe Ratio distribution charts can be found below:
* The bar in red indicates where Gentian Diagnostics AS's 1-Year Sharpe Ratio falls into.
Gentian Diagnostics AS 1-Year Sharpe Ratio Calculation
The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.
Gentian Diagnostics AS (OSL:GENT) has a 1-Year Sharpe Ratio of -0.67 as of Aug. 17, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Gentian Diagnostics AS and its competitors.
Is Gentian Diagnostics AS's 1-Year Sharpe Ratio too high?
Gentian Diagnostics AS's current 1-Year Sharpe Ratio is -0.67. Overall, Gentian Diagnostics AS has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gentian Diagnostics AS's 1-Year Sharpe Ratio compare to ABT and SYK?
Gentian Diagnostics AS's 1-Year Sharpe Ratio of -0.67 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Medical Devices & Instruments company?
A good 1-Year Sharpe Ratio depends on the Medical Devices & Instruments industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Gentian Diagnostics AS and its competitors. Gentian Diagnostics AS's current 1-Year Sharpe Ratio is -0.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gentian Diagnostics AS stock overvalued right now?
Based on GuruFocus' analysis, Gentian Diagnostics AS (OSL:GENT) is currently considered Significantly Undervalued. The stock's GF Value™ is kr59.56, compared to a current price of kr38.80 — trading 34.9% below its estimated fair value. The current 1-Year Sharpe Ratio is -0.67. Gentian Diagnostics AS's overall GF Score™ is 71/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Gentian Diagnostics AS (OSL:GENT), the current 1-Year Sharpe Ratio is -0.67 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gentian Diagnostics AS (OSL:GENT) Overvalued in 2026?
Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued.
The current stock price of kr38.80 is trading 34.9% below its estimated GF Value™ of kr59.56.
GuruFocus considers Gentian Diagnostics AS to be Significantly Undervalued.
Key valuation signals for OSL:GENT:
1-Year Sharpe Ratio: -0.67
GF Value™: kr59.56 vs. price of kr38.80 (34.9% below fair value)
No single metric tells the full story. See the OSL:GENT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
71GF Score
Get the complete analysis for OSL:GENT
1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:GENT has been successfully added to your 
